Ginipral concentrate for solution for infusion is used for short-term treatment of uncomplicated preterm labor:
suppression of uterine activity in patients with a gestational age of 22 to 37 weeks in the absence of medical or gynecological contraindications to tocolytic therapy. before turning the fetus from the transverse position. as an emergency measure in case of premature birth before transporting the pregnant woman to the hospital.
Composition
Active ingredient: hexoprenaline;
1 ampoule of 5 ml contains 0.025 mg of hexoprenaline sulfate;
Excipients: sodium metabisulfite (E 223), disodium edetate; sodium chloride, sulfuric acid, diluted (for pH adjustment) water for injections.
Contraindication
Hypersensitivity to hexaprenaline or to any component of the drug. Presence of any disease up to 22 weeks of pregnancy. Use of the drug as a tocolytic agent in patients with a history of ischemic heart disease or in patients with significant risk factors for the development of ischemic heart disease. Threatened miscarriage in the I and II trimesters of pregnancy. Any disease of the mother or fetus in which the preservation of pregnancy is dangerous, for example, severe toxemia, intrauterine infection, vaginal bleeding due to placenta previa, eclampsia or severe preeclampsia, placental abruption or umbilical cord compression. Intrauterine fetal death, fatal congenital anomalies in history or fatal chromosomal anomalies. Bronchial asthma with increased sensitivity to sulfates. Diseases of the cardiovascular system, in particular tachyarrhythmia, myocarditis, mitral valve defect. Hyperthyroidism. Severe liver and kidney diseases. Glaucoma.
Method of application
For jet injection or infusion.
The indicated dosage can only be used as a guideline, since tocolysis requires an individual approach to the patient.
Treatment with Ginipral should only be initiated by obstetricians/physicians experienced in the use of tocolytic agents. Treatment should only be administered in facilities that are properly equipped to provide continuous monitoring of maternal and fetal health.
Application features
Pregnant women
Ginipral is prescribed for use during pregnancy.
Children
The drug is not intended for use in children.
Drivers
The drug has no or negligible effect on the reaction rate when driving vehicles or using other mechanisms.
Overdose
Symptoms of overdose may include: a significant increase in the woman's heart rate, tremors, palpitations, headache, sweating.
Usually, to eliminate these symptoms, it is enough to reduce the dosage of the drug. To eliminate severe symptoms of overdose, the use of non-selective beta-blockers is recommended, which competitively inhibit the action of the drug Ginipral.
Side effects
The most common side effects of the drug Ginipral are associated with the pharmacological properties of beta-adrenomimetics. In order to eliminate or reduce the occurrence of undesirable effects, careful monitoring of hemodynamics, such as blood pressure, heart rate and appropriate adjustment of the drug dose, is carried out. These effects usually disappear after discontinuation of the drug.
Interaction
The drug Ginipral should not be used together with drugs containing ergot alkaloids, as well as with drugs containing calcium, vitamin D, dihydrotachysterol and mineralocorticoids.
Storage conditions
Store in the original packaging at a temperature not exceeding 25 °C.
Keep out of reach of children!
Shelf life - 3 years.
